Sanctuary Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Sanctuary Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.57M	Sell	81,827 -13,169	-14%	-$389K	0.01%	910
2026 Q1	$2.35M	Sell	94,996 -19,801	-17%	-$472K	0.01%	877
2025 Q4	$2.68M	Buy	114,797 +55,636	+94%	+$1.24M	0.01%	782
2025 Q3	$1.17M	Buy	59,161 +27,551	+87%	+$567K	0.01%	1202
2025 Q2	$686K	Sell	31,610 -12,809	-29%	-$302K	﹤0.01%	1424
2025 Q1	$1.08M	Sell	44,419 -15,028	-25%	-$338K	0.01%	1095
2024 Q4	$1.38M	Buy	59,447 +28,407	+92%	+$610K	0.01%	1066
2024 Q3	$667K	Buy	+31,040	New	+$575K	﹤0.01%	1521

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanctuary Advisors's CPRX Position: Q2 2026 in Review

Sanctuary Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 14% in Q2 2026, selling an estimated $389K and leaving 81,827 shares worth $2.57M. The position accounts for 0.01% of the portfolio, ranked #910.

Sanctuary Advisors first reported a position in CPRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.68M in Q4 2025. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Sanctuary Advisors held 81,827 shares of Catalyst Pharmaceutical worth $2.57M as of Q2 2026.
Sanctuary Advisors sold 13,169 Catalyst Pharmaceutical shares in Q2 2026, an estimated $389K.
Catalyst Pharmaceutical made up 0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #910 holding.
Sanctuary Advisors first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 8 quarters since.
Sanctuary Advisors's Catalyst Pharmaceutical position peaked at $2.68M in Q4 2025.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.